Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
age
cladribine tablets
lymphocyte subsets
lymphopenia
multiple sclerosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
08
2021
accepted:
10
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
2
2022
Statut:
epublish
Résumé
Cladribine tablets (CladT) preferentially reduce B and T lymphocyte levels. As aging is associated with a decline in immune function, the effect of CladT on lymphocyte levels may differ by age. This
Identifiants
pubmed: 35003076
doi: 10.3389/fimmu.2021.763433
pmc: PMC8740297
doi:
Substances chimiques
Tablets
0
Cladribine
47M74X9YT5
Banques de données
ClinicalTrials.gov
['NCT00213135', 'NCT00641537', 'NCT00725985']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
763433Informations de copyright
Copyright © 2021 Giovannoni, Coyle, Vermersch, Walker, Aldridge, Nolting, Galazka, Lemieux and Leist.
Déclaration de conflit d'intérêts
The authors declare that this study received funding from EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755). The funder had the following involvement with the study: designing the study, collecting and analyzing the data. The authors had full control of the manuscript and provided their final approval of all content. GG has received speaker honoraria and consulting fees from Abbvie, Actelion, Atara Bio, Almirall, Bayer Schering Pharma, Biogen Idec, Celgene-BMS, FivePrime, GlaxoSmithKline, GW Pharma, Janssen, Merck & Co., Merck Healthcare KGaA, Darmstadt, Germany, Pfizer Inc, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd, Sanofi-Genzyme, UCB, Vertex Pharmaceuticals, Ironwood, and Novartis; and research support unrelated to this study from Biogen Idec, Merck & Co., Novartis, and Ironwood. PKC declares being an advisor or consultant for Accordant, Biogen, Bristol Myers Squibb, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Mylan, Novartis, and Viela Bio, and receiving grants for clinical research from Actelion, Alkermes, Celgene, Corrona LLC, Genentech/Roche, MedDay, NINDS, and Novartis. PV has received honoraria or consulting fees from Biogen, Sanofi-Genzyme, Novartis, Merck Healthcare KGaA, Darmstadt, Germany, Celgene, Roche, AB Science, and Imcyse; and research support from Biogen, Sanofi-Genzyme, and Merck Healthcare KGaA, Darmstadt, Germany. BW has received consulting fees from Biogen, Celgene, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Novartis, and Sanofi-Genzyme. JA is an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA. AN is an employee of Merck Healthcare KGaA, Darmstadt, Germany. AG was employed by Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA at the time of the study. He is now a consultant for Merck Healthcare KGaA, Darmstadt, Germany. CL is an employee of EMD Inc. Mississauga, Ontario, Canada, an affiliate of Merck KGaA. TPL received consultancy fees or clinical research grants from Acorda, Bayer, Biogen, Daiichi, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Novartis, ONO, Pfizer and Teva Neuroscience.
Références
Cochrane Database Syst Rev. 2016 Mar 03;3:CD008858
pubmed: 26937872
Neurol Clin Pract. 2016 Jun;6(3):220-229
pubmed: 27347439
Curr Opin Neurol. 2019 Jun;32(3):305-312
pubmed: 30985373
Neurotherapeutics. 2021 Apr;18(2):1166-1174
pubmed: 33844155
Mult Scler. 2021 May 12;:13524585211012227
pubmed: 33975489
Scand J Immunol. 2016 Apr;83(4):255-66
pubmed: 26808160
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 29;3(3):e228
pubmed: 27213173
Immune Netw. 2019 Nov 14;19(6):e37
pubmed: 31921467
J Neurovirol. 2017 Oct;23(5):742-749
pubmed: 28791614
Mult Scler Relat Disord. 2019 Apr;29:168-174
pubmed: 30885375
Immunol Rev. 2005 Jun;205:7-17
pubmed: 15882341
Neurotherapeutics. 2017 Oct;14(4):874-887
pubmed: 29168160
Front Neurol. 2017 Nov 10;8:577
pubmed: 29176956
Front Immunol. 2019 Sep 25;10:2247
pubmed: 31608061
Mult Scler. 2018 Jul;24(8):1014-1022
pubmed: 29774781
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304
pubmed: 22056965
Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35
pubmed: 21242742
Ann N Y Acad Sci. 2015 Sep;1351:11-21
pubmed: 25943573
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
Front Immunol. 2018 Jan 10;8:1960
pubmed: 29375577
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Neurology. 2019 Mar 5;92(10):e1029-e1040
pubmed: 30770430
Drugs. 2020 Dec;80(18):1901-1928
pubmed: 33247831
Mult Scler. 2013 Oct;19(11):1533-8
pubmed: 23459571
Neurol Clin Pract. 2019 Feb;9(1):53-63
pubmed: 30859008
Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477
pubmed: 30027104
Immunity. 2006 May;24(5):495-9
pubmed: 16713964
J Immunol. 2013 Dec 15;191(12):5867-74
pubmed: 24198283
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
Mult Scler J Exp Transl Clin. 2017 Oct 09;3(4):2055217317732802
pubmed: 29051829
Lancet Neurol. 2011 Apr;10(4):329-37
pubmed: 21397565